Regulatory Compliance Clarification from Sun Pharma Advanced Research Company Limited
Summary of Company's Response
Sun Pharma Advanced Research Company Limited (SPARC) has formally responded to a query from the National Stock Exchange of India Ltd. (NSE) regarding unusual trading activity in its securities.
Date and Nature of Exchange Query
- Date of NSE Communication: November 09, 2026
- Nature of Query: The exchange sought clarification regarding an increase in trading volume of SPARC shares
- Company Response Date: November 11, 2026 at 11:18:11 IST
Company's Clarification on Trading Volume
SPARC confirmed through its Company Secretary and Compliance Officer, Kajal Damania, that the company is in full compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company explicitly stated that it is not aware of any information that qualifies for disclosure under these regulations but has not been disclosed to the exchanges.
Regulatory Compliance Reference
The response specifically references compliance with:
- Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- All required disclosures under this regulation have been made to the exchanges
Financial Results Clarification
No specific financial results were discussed or clarified in this communication. The response focused exclusively on regulatory compliance and trading volume matters.